Alpha Teknova, Inc.
TKNO Healthcare Drug Manufacturers Specialty & Generic
Alpha Teknova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 7.35% from fiscal 2024. In the quarter to June 2026, revenue grew 18.5%, EPS grew 14.3%, free cash flow grew 74.2% and total debt rose 1.43%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow TKNO
Alpha Teknova, Inc. (TKNO) EV/Sales
As of 16 October 2026, Alpha Teknova, Inc. (TKNO) trades at a EV/Sales of 8.7×. Over the past ten years it has ranged from −0.6× (July 2021) to 17.9× (October 2021); the current reading is higher than 85% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.9× | (50.34%) |
| FY2024 | 9.9× | 237.76% |
| FY2023 | 2.9× | (13.21%) |
| FY2022 | 3.4× | (50.95%) |
| FY2021 | 6.9× | 170.18% |
| FY2020 | 2.5× | 0.00% |
| FY2019 | 2.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.0× | 88.69% |
| Mar 2026 | 3.7× | (24.84%) |
| Dec 2025 | 4.9× | (40.07%) |
| Sep 2025 | 8.2× | 24.88% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLRY Tilray Brands, Inc. compare | 0.6× |
| EVO Evotec AG compare | 0.6× |
| EBS Emergent Biosolutions Inc. compare | 1.0× |
| CGC Canopy Growth Corporation compare | 1.1× |
| KMDA Kamada Ltd. compare | 2.1× |
| EOLS Evolus, Inc. compare | 2.1× |
| ANIK Anika Therapeutics Inc. compare | 2.1× |
| AQST Aquestive Therapeutics, Inc. compare | 7.9× |
| TKNO Alpha Teknova, Inc. | 8.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)